Abstract:The pandemic caused by emerging coronavirus SARS-CoV-2 presents a serious global public health emergency in urgent need of prophylactic and therapeutic interventions. SARS-CoV-2 cellular entry depends on binding between the viral Spike protein receptor-binding domain (RBD) and the angiotensin converting enzyme 2 (ACE2) target cell receptor. Here, we report on the isolation and characterization of 206 RBD-specific monoclonal antibodies (mAbs) derived from single B cells of eight SARS-CoV-2 infected individuals. These mAbs come from diverse families of antibody heavy and light chains without apparent enrichment for particular families in the repertoire. In samples from one patient selected for further analyses, we found coexistence of germline and germline divergent clones. Both clone types demonstrated impressive binding and neutralizing activity against pseudovirus and live SARS-CoV-2. However, the antibody neutralizing potency is determined by competition with ACE2 receptor for RBD binding. Surprisingly, none of the SARS-CoV-2 antibodies nor the infected plasma cross-reacted with RBDs from either SARS-CoV or MERS-CoV although substantial plasma cross-reactivity to the trimeric Spike proteins from SARS-CoV and MERS-CoV was found. These results suggest that antibody response to RBDs is viral species-specific while that cross-recognition target regions outside the RBD. The specificity and neutralizing characteristics of this plasma cross-reactivity requires further investigation. Nevertheless, the diverse and potent neutralizing antibodies identified here are promising candidates for prophylactic and therapeutic SARS-CoV-2 interventions.

IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity

A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction

Human Monoclonal Antibodies Block the Binding of SARS-CoV-2 Spike Protein to Angiotensin Converting Enzyme 2 Receptor.

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

Recombinant neutralizing secretory IgA antibodies for preventing mucosal acquisition and transmission of SARS-CoV-2

Potently neutralizing and protective human antibodies against SARS-CoV-2

Monoclonal Antibodies Capable of Binding SARS-CoV-2 Spike Protein Receptor-Binding Motif Specifically Prevent GM-CSF Induction.

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Potent human neutralizing antibodies elicited by SARS-CoV-2 infection

In vitro antibody-mediated SARS-CoV-2 infection suppression through human ACE2 receptor blockade

A Human Monoclonal Antibody Neutralizes SARS-CoV-2 Omicron Variants by Targeting the Upstream Region of Spike Protein HR2 Motif

A SARS-CoV-2 neutralizing antibody with exceptional spike binding coverage and optimized therapeutic potentials

Broadly potent spike-specific human monoclonal antibodies inhibit SARS-CoV-2 Omicron sub-lineages

Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain

Human IgG Neutralizing Monoclonal Antibodies Block SARS-CoV-2 Infection

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes

A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes

Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?